Kishor Bhatia
Fortuna: - $ al 31/08/2026
Fortuna: - $ al 31/08/2026
Kishor G.
Bhatia currently works at Lantern Pharma, Inc., as Chief Scientific Officer from 2019.
Dr. Bhatia also formerly worked at National Cancer Institute, as Director-AIDS Malignancy Program from 2007 to 2016 and Georgetown University, as Research Assistant Professor from 1985 to 1989.
Dr. Bhatia received his doctorate degree from the University of Mumbai and undergraduate degree from the University of Pune.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LANTERN PHARMA, INC. -.--% | 17/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LANTERN PHARMA INC. | Director Técnico/Científico/I+D | 01/12/2019 |
| Empresas | Cargo | Fin |
|---|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Corporate Officer/Principal | 01/07/2016 |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1989 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Mumbai
University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
University of Pune
University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.